Business
ARIUS Named to TSX Venture Top 50
ARIUS Named to TSX Venture Top 50.
About this update from Affinity Metals Corp
[{"type":"text","content":"\n\n\n\n\n(TSX Venture: ARI)\n\nTORONTO, Dec. 6 /CNW/ - ARIUS Research Inc. (TSX-V - ARI) is pleased to\nannounce that it has been selected as one of the 2005 TSX Venture 50, a\nranking of the top 50 public venture capital companies listed on the TSX\nVenture Exchange. The project was initiated by the Exchange with PROFIT\nMagazine to highlight quality Canadian companies that are using public venture\ncapital to achieve growth. The criteria used to compile the list include\nrevenue, return on investment, market capitalization growth and trading\nvolume.\n\nThe inaugural TSX Venture 50 will be published in the following\npublications:\n\n - PROFIT Magazine (December issue)\n - Canadian Business Magazine (December 26 issue)\n - L'ActualitDe (February issue)\n\n\"There are over 2000 companies on the TSX Venture Exchange and we are\nhonoured to be included among the Top 50,\" said Dr. David S. Young, President\nand Chief Scientific Officer of ARIUS. \"There is a broad consensus that\nbiotechnology is an important area of growth for the Canadian economy. An\nexample of its increasing prominence is the recent creation of the Ministry of\nResearch and Innovation in Ontario. We believe that companies such as ours\nhave an important mission to advance the health and welfare of Canadians. We\nthank the TSXV for this timely recognition of our technology, our business\nstrategy and our potential for growth in this important area of commercial\nendeavour.\"\n\nAbout ARIUS Research\n\nARIUS Research Inc. is a biotechnology company dedicated to the discovery\nand development of novel anticancer monoclonal antibodies (MAbs). Established\nin 1999, ARIUS has built a proprietary technology platform, FunctionFIRST(TM),\nthat rapidly identifies powerful MAbs targeting a variety of cancer\nindications. This antibody generation engine has enabled ARIUS to assemble a\ngrowing pipeline of over 300 functional MAbs, which may be used for commercial\ncollaborations, out-licensing or in-house development. ARIUS has ongoing\nlicensing and research partnerships with key biotechnology and drug\ndevelopment companies that provide revenues and access to external\ntechnologies. The long-term vision of ARIUS is to deliver personalized therapy\nby matching multiple antibodies to the distinct antigenic characteristics of\neach patient's tumor cells thereby increasin...